KORU Medical Systems (KRMD) investor relations material

Business overview and market positioning

• Specializes in large-volume subcutaneous drug delivery, supporting the shift from IV hospital settings to home and clinic-based SC therapy.

• Freedom Infusion System serves approximately 60,000 chronic SCIg therapy patients globally.

• Collaborates with eight pharmaceutical companies to expand indications and market reach.

• Operates with a low-cost go-to-market model, leveraging partnerships with pharma, specialty pharmacies, and distributors.

Product portfolio and innovation

• Freedom Infusion System includes mechanical pumps and customizable consumables, with 97% patient adherence.

• 80% of revenues come from consumables, 20% from mechanical pumps.

• First devices 510(k) cleared for use with prefilled syringes, simplifying home therapy.

• Pipeline includes 8 active opportunities for new drugs and indications, with 9 drugs currently on label.

Financial performance and guidance

• FY2025 revenues reached $41.1M; FY2026 guidance is $47.5–$48.5M, reflecting 15–18% year-over-year growth.

• Gross margin projected at 62–64% for FY2026, with positive adjusted EBITDA and year-end cash balance over $7.5M.

• 1H 2026 revenue grew 20% year-over-year, with a 63.3% gross margin and significant improvement in adjusted EBITDA.

• Long-term goals include $100M revenue, >65% gross margins, and +20% EBITDA margin.